CRISPR Therapeutics (CRSP) Earnings Analysis
CRISPR Therapeutics (CRSP) next reports earnings on 2026-08-03, consensus EPS -1.19931 USD. Last quarter (2026-05-04) it missed with EPS -1.28 USD vs -1.18964 USD est (-7.6%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -7.59.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CRSP next report earnings?
| Next earnings date | 2026-08-03 |
|---|---|
| Consensus EPS estimate | -1.19931 USD |
| Revenue estimate | 0.01B |
CRSP earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-04 | -1.28 USD | -1.18964 USD | -7.6% | Miss |
| 2026-02-12 | -1.37 USD | -1.15 USD | -19.1% | Miss |
| 2025-11-10 | -1.17 USD | -1.26 USD | +7.1% | Beat |
| 2025-08-04 | -1.29 USD | -1.47 USD | +12.2% | Beat |
| 2024-08-05 | -1.49 USD | -1.37 USD | -8.8% | Miss |
Beat rate: 2/5 (40%) over reported quarters with consensus data.
CRSP valuation and analyst view
| Trailing P/E | -7.59 |
|---|---|
| Trailing EPS | -5.91907 USD |
| Price / book | 2.50 |
| Dividend yield | 0.00% |
| Market cap | 4.54B |
| Analyst consensus | Buy (22 buy / 14 hold / 2 sell) |
| Avg price target | 70.4 USD |
Related research pages
Frequently asked questions
When is CRISPR Therapeutics (CRSP)'s next earnings date?
CRISPR Therapeutics is next scheduled to report on 2026-08-03, with a consensus EPS estimate of -1.19931 USD and revenue estimate of 0.01B.
Did CRSP beat earnings last quarter?
In its 2026-05-04 report, CRSP posted EPS of -1.28 USD versus a -1.18964 USD estimate — a miss of 7.6%.
What is CRSP's earnings track record?
Over the last 5 reported quarters with consensus data, CRSP beat estimates 2 times (40%).
What is CRSP's current P/E ratio and EPS?
CRSP trades at a trailing P/E of -7.59 on trailing EPS of -5.919070602616346 USD.
What do analysts rate CRSP?
Analyst consensus is "Buy" across 38 ratings (0 strong buy, 22 buy, 14 hold, 2 sell, 0 strong sell). Average 12-month price target: 70.4 USD.